Skip to main content
Clinical Trials/ACTRN12619001548123
ACTRN12619001548123
Recruiting
Phase 3

Double NAC trial: Investigation of increased N-acetylcysteine dosing in patients treated for paracetamol overdose.

Monash Health0 sites230 target enrollmentNovember 11, 2019

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
paracetamol overdose
Sponsor
Monash Health
Enrollment
230
Status
Recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 11, 2019
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Patients requiring NAC following single acute or staggered overdose with abnormal liver function tests on presentation (ALT\>40 U/L), or paracetamol concentration more than double the nomogram treatment line, modified\-release paracetamol paracetamol ingestions.

Exclusion Criteria

  • Exclusion criteria will be patients who are pregnant, intoxicated or sedated patients with co\-ingested alcohol or sedating drugs. Single acute overdose patients who are at low risk \- normal ALT (\<40 IU/L) and paracetamol concentrations less than double the nomogram treatment line will be excluded. Patients with an ALT \>40 IU/L on admission and documented preexisting liver disease will be excluded.

Outcomes

Primary Outcomes

Not specified

Similar Trials